NIKKEI 225
38,189.54 -216.12 (-0.56%) HANG SENG
17,763.03 +16.12 (+0.09%) CRUDE OIL
81.16 -0.77 (-0.94%) GOLD FUTURES
2,296.60 -6.30 (-0.27%) DOW
37,815.92 -570.17 (-1.49%) Bitcoin GBP
48,190.93 -2,802.34 (-5.50%)
Innovent Biologics, Inc. (1801.HK)
| Previous close | 39.750 |
| Open | 39.500 |
| Bid | 38.250 x 0 |
| Ask | 38.350 x 0 |
| Day's range | 38.000 - 40.400 |
| 52-week range | 27.300 - 49.800 |
| Volume | |
| Avg. volume | 9,362,664 |
| Market cap | 62.035B |
| Beta (5Y monthly) | 0.17 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.710 |
| Earnings date | 20 Mar 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 56.15 |
PR NewswireInnovent Announces the Appointment of Dr. Samuel Zhang as Global Chief Business Officer (CBO)
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, today announces the appointment of Dr. Samuel Zhang as its Global Chief Business Officer (CBO). In this role, Dr. Zhang will be responsible for Innovent's global strategy and business development, and his reporting line is Dr.
PR NewswireInnovent to Present Clinical Data of Multiple Novel Molecules at the 2024 ASCO Annual Meeting
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that about 20 accepted abstracts of clinical data from multiple trials in relation to multiple novel mono-/bi-specific antibodies and antibody-drug-conjugates (ADCs) as well as innovative drugs including TYVYT® (si
PR NewswireInnovent Announces the Appointment of Dr. Nageatte Ibrahim as the Oncology Chief Medical Officer (CMO)
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announces the appointment of Dr. Nageatte Ibrahim, a world-famous Oncology Clinical Development Leader in the Pharmaceutical Industry, as the Oncology CMO. Dr. Ibrahim will provide the strategy, execution and leadership for the Oncology Global Clinical D
